发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:Uncontrollable cell proliferation and irreversible neurological damage make glioma one of the most deadly diseases in clinic. Besides the multiple biological barriers, glioma stem cells (GSCs) that are responsible for the maintenance and recurrence of tumor tissues also hinder the therapeutic efficacy of chemotherapy. Therefore, all-stage precisional glioma targeted therapy regimens that could efficiently deliver drugs to glioma cells and GSCs after overcoming multiple barriers have received increasing scrutiny. Methods: A polymeric micelle-based drug delivery system was developed by modifying a "Y-shaped" well-designed ligand of both GRP78 protein and quorum sensing receptor to achieve all-stage precisional glioma targeting, then we evaluated the targeting ability and barrier penetration ability both in vitro and in vivo. In order to achieve all-stage precisional therapy, we need kill both GSCs and glioma related cells. Parthenolide (PTL) has been investigated for its selective toxicity to glioma stem cells while Paclitaxel (PTX) and Temozolomide (TMZ) are widely used in experimental and clinical therapy of glioma respectively. So the in vivo anti-glioma effect of combination therapy was evaluated by Kaplan-Meier survival analysis and immunohistochemical (IHC) examination of tumor tissues. Results: The "Y-shaped" well-designed peptide, termed DWVAP, exhibited excellent glioma (and GSCs) homing and barrier penetration ability. When modified on micelle surface, DWVAP peptide significantly enhanced accumulation of micelles in brain and glioma. In addition, DWVAP micelles showed no immunogenicity and cytotoxicity, which could guarantee their safety when used in vivo. Treatment of glioma-bearing mice with PTL loaded DWVAP modified PEG-PLA micelles plus PTX loaded DWVAP modified PEG-PLA micelles or PTL loaded DWVAP modified PEG-PLA micelles plus TMZ showed improved anti-tumor efficacy in comparison to PTL and PTX loaded unmodified micelles or PTL loaded unmodified micelles plus TMZ. Conclusion: Combination of all-stage targeting strategy and concomitant use of chemotherapeutics and stem cell inhibitors could achieve precise targeted therapy for glioma.
展开更多
最新影响因子:11.6 | 期刊ISSN:1838-7640 | CiteScore:8.7 |
出版周期: | 是否OA:YES | 出版年份:2011 |
期刊官方网址:http://www.thno.org/
自引率:7.70% | 研究方向:MEDICINE, RESEARCH & EXPERIMENTAL- |
出版地区:AUSTRALIA |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The aim of Theranostics is to provide a forum for the exchange of clinical and scientific information for the diagnostic and therapeutic molecular and nano medicine community and allied professions involved in the efforts of integrating molecular imaging and molecular therapy. Theranostics is a multidisciplinary journal that publishes innovative and original research articles reflecting fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensor, nanobiosensor and bioelectronics, system biology and translational medicine, point-of-care and personalized medicine. A broad spectrum of biomedical research that can be applied to future theranostic applications is encouraged. In addition to primary research, Theranostics also publishes reviews, news, and commentary to understand and bridge the gap among the laboratory, clinic, and biotechnology industries. Papers in the journal are rigorously peer-reviewed.
Theranostics的目的是为诊断和治疗分子和纳米医学社区以及相关专业提供一个交流临床和科学信息的论坛,这些专业致力于将分子成像和分子治疗结合起来。Theranostics是一份多学科期刊,发表创新和原创的研究文章,反映了体外诊断和预测、体内分子成像、分子治疗、图像引导治疗、生物传感器、纳米生物传感器和生物电子学、系统生物学和转化医学、定点医疗和个性化医疗等领域。鼓励广泛的生物医学研究,可应用于未来的theranostic应用。除了初级研究,Theranostics还出版评论、新闻和评论,以了解和弥合实验室、临床和生物技术行业之间的差距。杂志上的论文都经过严格的同行评审。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
MEDICINE, RESEARCH & EXPERIMENTAL (医学:研究与实验) 2区 |
8/133 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
353 | 323 | 30 |
引文计数(2018)
文献(2015-2017)
3480次引用
400篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Medicine (miscellaneous)
|
#4/189
点击查看排名表
|
|
2 |
大类(学科):Pharmacology, Toxicology and Pharmaceutics
小类(学科):Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
|
#1/22
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:治疗靶点 分子生物 生物治疗
接受率: 比较困难(25%命中)
liting7111
liting7111
研究方向:药物性肝损伤 自噬
接受率: 比较困难(25%命中)
liting7111
研究方向:医药科学 肿瘤学 肿瘤发生
审稿时间: 5个月内
liting7111
研究方向:炎症 表观遗传
影响因子:2.438
ISSN:0261-1929
研究方向:农林科学-兽医学
影响因子:3.025
ISSN:1094-7159
研究方向:医学-临床神经学
影响因子:4.169
ISSN:0264-410X
研究方向:医学-免疫学
影响因子:17.579
ISSN:0022-1007
研究方向:医学-免疫学
影响因子:5.274
ISSN:0971-5916
研究方向:医学-免疫学
影响因子:4.061
ISSN:2314-6745
研究方向:ENDOCRINOLOGY & METABOLISM-MEDICINE, RESEARCH & EX
影响因子:2.976
ISSN:0914-8779
研究方向:医学-内分泌学与代谢
影响因子:4.75
ISSN:0141-8955
研究方向:医学-内分泌学与代谢
影响因子:10.171
ISSN:1931-5244
研究方向:医学-医学:内科
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
Theranostics 投稿经验
(由下方点评分析获得,6人参与,21520人阅读)